Skip to main content
Kane Biotech
Biofilms
Overview
Understanding Biofilms
coactiv+™
DispersinB
®
Glossary Of Terms
About
Our Team
Contact
Publications
Publications / Posters
News / Events
Investors
Overview
News / Events
Company Information
Financial Results
Stock Data
SEDAR
Corporate Governance
Press Releases
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
Investors
Overview
News / Events
Press Releases
IR Calendar
Email Alerts
Company Info
Profile
Presentations
Management Team
Contacts
Financial Results
Stock Data
TSX-V:KNE
SEDAR
Governance
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
News / Events
Press Releases
IR Calendar
Email Alerts
All News
2025
2024
2023
Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024
Nov 21, 2024
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
Nov 14, 2024
Kane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement
Nov 14, 2024
Kane Biotech Announces Agreement to Acquire FB Dermatology
Nov 12, 2024
Kane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to Ukraine
Oct 23, 2024
Kane Biotech Announces Exclusive Distribution Agreement With XSONX
Oct 17, 2024
Kane Biotech to Participate in a Multinational Corporate Collaboration Project
Oct 3, 2024
Kane Biotech Announces Attendance at Upcoming Wound Care Conferences
Sep 26, 2024
Kane Biotech Announces Exercise of Warrants
Sep 12, 2024
Kane Biotech Announces Second Quarter 2024 Financial Results
Aug 29, 2024
1
2
3
4
5
6
7
8
9
